Aline Guillot

1.6k total citations
62 papers, 1.0k citations indexed

About

Aline Guillot is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Aline Guillot has authored 62 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Pulmonary and Respiratory Medicine, 29 papers in Oncology and 18 papers in Surgery. Recurrent topics in Aline Guillot's work include Prostate Cancer Treatment and Research (20 papers), Renal cell carcinoma treatment (18 papers) and Cancer Treatment and Pharmacology (15 papers). Aline Guillot is often cited by papers focused on Prostate Cancer Treatment and Research (20 papers), Renal cell carcinoma treatment (18 papers) and Cancer Treatment and Pharmacology (15 papers). Aline Guillot collaborates with scholars based in France, Spain and Italy. Aline Guillot's co-authors include Stéphane Oudard, Bernard Escudier, Laurence Albigès, Sylvestre Le Moulec, Christine Théodore, Christophe Massard, Thibault De La Motte Rouge, Gwénaëlle Gravis, Philippe Beuzeboc and Karim Fizazi and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and British Journal of Cancer.

In The Last Decade

Aline Guillot

59 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aline Guillot France 16 692 426 330 315 206 62 1.0k
D.Y.C. Heng Canada 18 652 0.9× 400 0.9× 314 1.0× 372 1.2× 98 0.5× 55 927
Ana B. Oton United States 18 1.1k 1.6× 418 1.0× 237 0.7× 1.0k 3.3× 84 0.4× 39 1.7k
Enrique Gallardo Spain 18 621 0.9× 500 1.2× 315 1.0× 480 1.5× 571 2.8× 90 1.6k
Lara Pijuán Spain 20 680 1.0× 307 0.7× 311 0.9× 571 1.8× 168 0.8× 74 1.3k
Florian Kocher Austria 18 357 0.5× 215 0.5× 160 0.5× 498 1.6× 130 0.6× 72 990
Laura Visa Spain 15 417 0.6× 180 0.4× 334 1.0× 662 2.1× 262 1.3× 37 1.0k
Gavin W.A. Lamb United Kingdom 13 447 0.6× 177 0.4× 216 0.7× 632 2.0× 216 1.0× 14 918
Sanjaykumar Hapani United States 6 362 0.5× 216 0.5× 85 0.3× 577 1.8× 158 0.8× 9 1.0k
Brandon Bernard United States 15 639 0.9× 275 0.6× 247 0.7× 225 0.7× 254 1.2× 39 992
Jurjees Hasan United Kingdom 15 197 0.3× 326 0.8× 185 0.6× 371 1.2× 150 0.7× 53 919

Countries citing papers authored by Aline Guillot

Since Specialization
Citations

This map shows the geographic impact of Aline Guillot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aline Guillot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aline Guillot more than expected).

Fields of papers citing papers by Aline Guillot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aline Guillot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aline Guillot. The network helps show where Aline Guillot may publish in the future.

Co-authorship network of co-authors of Aline Guillot

This figure shows the co-authorship network connecting the top 25 collaborators of Aline Guillot. A scholar is included among the top collaborators of Aline Guillot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aline Guillot. Aline Guillot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Grenga, Lucia, Catherine Dunyach‐Remy, Guilhem Roubaud, et al.. (2025). Gut microbiota as a biomarker for the efficacy of pembrolizumab in patients with advanced urothelial carcinoma treated in a prospective multicenter study.. Journal of Clinical Oncology. 43(5_suppl). 825–825. 1 indexed citations
2.
3.
Barthélémy, Philippe, Yohann Loriot, Aude Fléchon, et al.. (2023). 2379P AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM). Annals of Oncology. 34. S1211–S1212. 2 indexed citations
4.
Borchiellini, Delphine, Aline Guillot, Jean-Baptiste Paoli, et al.. (2021). TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 19(6). 501–509. 34 indexed citations
5.
Guillot, Aline, Philippe Barthélémy, Sylvie Négrier, et al.. (2018). Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study. Clinical Genitourinary Cancer. 17(1). e38–e43. 13 indexed citations
6.
Méry, Benoîte, et al.. (2018). Cancer du rein métastatique : recommandations et perspectives en 1re ligne. Bulletin du Cancer. 105. S235–S241. 1 indexed citations
7.
Delanoy, Nicolas, Antoine Angelergues, Eleni Efstathiou, et al.. (2017). Sequencing in metastatic castration-resistant prostate cancer (mCRPC): Updated results of the FLAC International Database.. Journal of Clinical Oncology. 35(6_suppl). 267–267. 2 indexed citations
8.
Joly, Florence, Aline Guillot, Yann Vano, et al.. (2017). Enquête nationale française sur les appels téléphoniques entrants en oncologie médicale. Bulletin du Cancer. 104(6). 565–573. 1 indexed citations
9.
10.
Médioni, Jacques, Mario Di Palma, Aline Guillot, Dominique Spaëth, & Christine Théodore. (2016). Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study. BMC Cancer. 16(1). 217–217. 15 indexed citations
11.
Guillot, Aline, Philippe Barthélémy, Sylvie Négrier, et al.. (2016). Denosumab in patients with bone metastases from renal-cell carcinoma treated with anti-angiogenic therapy: a retrospective study from the GETUG (Groupe Etude des Tumeurs Uro Genitales). Annals of Oncology. 27. vi289–vi289. 3 indexed citations
12.
Houédé, Nadine, Gottfried J. Locker, Héctor Soto Parrà, et al.. (2016). Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy. BMC Cancer. 16(1). 752–752. 5 indexed citations
13.
Méry, Benoîte, Alexander T. Falk, Jane‐Chloé Trone, et al.. (2015). Hypofractionated radiation therapy for treatment of bladder carcinoma in patients aged 90 years and more: A new paradigm to be explored?. International Urology and Nephrology. 47(7). 1129–1134. 6 indexed citations
14.
Thiery-Vuillemin, Antoine, Christine Théodore, Lutz Jacobasch, et al.. (2014). Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study. Clinical Genitourinary Cancer. 13(3). 231–238. 8 indexed citations
15.
Angelergues, Antoine, Denis Maillet, Aude Fléchon, et al.. (2014). Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. European Journal of Cancer. 50(9). 1602–1609. 36 indexed citations
16.
Nakouzi, Nader Al, Sylvestre Le Moulec, Laurence Albigès, et al.. (2014). Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. European Urology. 68(2). 228–235. 134 indexed citations
17.
Guillot, Aline, Antonin Lévy, Olivier Collard, et al.. (2012). Reappraisal of the Role of Bevacizumab in the Therapeutic Strategy in Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer. 10(3). 147–152. 2 indexed citations
18.
Malouf, Gabriel G., Philippe Camparo, Stéphane Oudard, et al.. (2010). Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Annals of Oncology. 21(9). 1834–1838. 158 indexed citations
19.
Prades, Jean‐Michel, et al.. (2002). Concomitant Chemoradiotherapy in Pyriform Sinus Carcinoma. Archives of Otolaryngology - Head and Neck Surgery. 128(4). 384–384. 30 indexed citations
20.
Tranchand, Brigitte, Sylvie Zanetta, Aline Guillot, et al.. (1999). A Sensitive Docetaxel Assay in Plasma by Solid-Phase Extraction and High Performance Liquid Chromatography – UV Detection: Validation and Suitability in Phase I Clinical Trial Pharmacokinetics. Investigational New Drugs. 17(4). 325–333. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D.Y.C. Heng Breakdown of academic impact, for papers by Ana B. Oton Breakdown of academic impact, for papers by Enrique Gallardo Breakdown of academic impact, for papers by Lara Pijuán Breakdown of academic impact, for papers by Florian Kocher Breakdown of academic impact, for papers by Laura Visa Breakdown of academic impact, for papers by Gavin W.A. Lamb Breakdown of academic impact, for papers by Sanjaykumar Hapani Breakdown of academic impact, for papers by Brandon Bernard Breakdown of academic impact, for papers by Jurjees Hasan
Rankless by CCL
2026